相似文献
1
The resistance mechanisms of proteasome inhibitor bortezomib.
Biomark Res. 2013 Mar 1;1(1):13. doi: 10.1186/2050-7771-1-13.
2
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
Blood. 2008 Sep 15;112(6):2489-99. doi: 10.1182/blood-2007-08-104950. Epub 2008 Jun 18.
3
Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
J Pharmacol Exp Ther. 2008 Aug;326(2):423-31. doi: 10.1124/jpet.108.138131. Epub 2008 May 23.
4
Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
J Hematol Oncol. 2014 Jan 13;7:7. doi: 10.1186/1756-8722-7-7.
5
Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
J Pharmacol Exp Ther. 2012 Apr;341(1):174-82. doi: 10.1124/jpet.111.187542. Epub 2012 Jan 10.
6
Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
Biochem Pharmacol. 2012 Jan 15;83(2):207-17. doi: 10.1016/j.bcp.2011.10.009. Epub 2011 Oct 18.
7
Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
Exp Hematol. 2009 Jul;37(7):831-7. doi: 10.1016/j.exphem.2009.04.001. Epub 2009 May 6.
8
Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Mol Pharmacol. 2014 Jul;86(1):12-9. doi: 10.1124/mol.114.092114. Epub 2014 Apr 15.
9
Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Exp Hematol. 2008 Oct;36(10):1278-84. doi: 10.1016/j.exphem.2008.04.013. Epub 2008 Jun 17.
10
Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
J Biol Chem. 2014 May 2;289(18):12612-22. doi: 10.1074/jbc.M113.542829. Epub 2014 Mar 13.
引用本文的文献
1
PPM1D is directly degraded by proteasomes in a ubiquitination-independent manner through its carboxyl-terminal region.
J Biomed Sci. 2025 Sep 11;32(1):88. doi: 10.1186/s12929-025-01185-z.
2
Dissolution Enhancement of Lycopene Compacts by Liquisolid Technique.
Turk J Pharm Sci. 2025 Sep 5;22(4):246-260. doi: 10.4274/tjps.galenos.2025.36559.
3
From oncogenesis to prognosis: the roles of the immunoproteasome in cancer.
Front Immunol. 2025 Jul 8;16:1603816. doi: 10.3389/fimmu.2025.1603816. eCollection 2025.
4
Suppressing proteasome activity enhances sensitivity to actinomycin D in diffuse anaplastic Wilms tumor.
Cell Rep Med. 2025 May 20;6(5):102133. doi: 10.1016/j.xcrm.2025.102133. Epub 2025 May 9.
5
Pharmacological Modulation of the Unfolded Protein Response as a Therapeutic Approach in Cutaneous T-Cell Lymphoma.
Biomolecules. 2025 Jan 7;15(1):76. doi: 10.3390/biom15010076.
6
Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients.
Curr Issues Mol Biol. 2025 Jan 6;47(1):32. doi: 10.3390/cimb47010032.
7
Comparative Analysis of Acquired Resistance to Bortezomib in Prostate Cancer Cells Using Proteomic and Bioinformatic Tools.
J Cell Mol Med. 2025 Jan;29(1):e70254. doi: 10.1111/jcmm.70254.
8
Characterization of driver mutations identifies gene signatures predictive of prognosis and treatment sensitivity in multiple myeloma.
Oncologist. 2024 Nov 4;29(11):e1552-e1564. doi: 10.1093/oncolo/oyae244.
9
Different Strategies to Overcome Resistance to Proteasome Inhibitors-A Summary 20 Years after Their Introduction.
Int J Mol Sci. 2024 Aug 16;25(16):8949. doi: 10.3390/ijms25168949.
10
Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties.
Sci Rep. 2024 Aug 13;14(1):18772. doi: 10.1038/s41598-024-69465-6.
本文引用的文献
1
Molecular mechanisms of acquired proteasome inhibitor resistance.
J Med Chem. 2012 Dec 13;55(23):10317-27. doi: 10.1021/jm300434z. Epub 2012 Oct 3.
2
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Cancer Cell. 2012 Sep 11;22(3):345-58. doi: 10.1016/j.ccr.2012.08.007.
3
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
Blood. 2012 Oct 18;120(16):3260-70. doi: 10.1182/blood-2011-10-386789. Epub 2012 Aug 29.
4
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Br J Haematol. 2012 Sep;158(6):739-48. doi: 10.1111/j.1365-2141.2012.09232.x. Epub 2012 Jul 30.
5
[Regulation of miRNA-15a/-16 expression on the drug resistance of myeloma cells].
Zhonghua Yi Xue Za Zhi. 2012 Apr 24;92(16):1100-3.
6
Relapsed/Refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance.
Semin Hematol. 2012 Jul;49 Suppl 1:S3-15. doi: 10.1053/j.seminhematol.2012.05.005.
7
Rad knockdown induces mitochondrial apoptosis in bortezomib resistant leukemia and lymphoma cells.
Leuk Res. 2012 Sep;36(9):1172-8. doi: 10.1016/j.leukres.2012.05.004. Epub 2012 Jun 2.
8
The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
Leuk Res. 2012 Jul;36(7):912-20. doi: 10.1016/j.leukres.2012.02.010. Epub 2012 May 5.
9
Differentiation induction enhances bortezomib efficacy and overcomes drug resistance in multiple myeloma.
Biochem Biophys Res Commun. 2012 Apr 13;420(3):644-50. doi: 10.1016/j.bbrc.2012.03.056. Epub 2012 Mar 17.
10
Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
APMIS. 2012 Mar;120(3):195-203. doi: 10.1111/j.1600-0463.2011.02836.x. Epub 2011 Nov 11.
Zotero 插件
